Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
Cassiopea SpA, a clinical-stage pharmaceutical company developing and commercializing innovative medical dermatology products, today announced very positive results of the twelve months phase II dose ranging clinical trial in men with androgenic alopecia (AGA) for its topical anti-androgen Clascoterone (Breezula®) solution. The results show statistically significant improvement versus vehicle (placebo) for Target Area Hair Count (TAHC) for every dose tested along with directional improvement for Hair Growth Assessment (HGA). The results also indicate an excellent safety profile, similar to vehicle, for both adverse events and local skin reactions, even after 12 months treatment.